Ida Deleskog Lindstrom, Global Medical Affairs Director at Gene Solutions, shared a post on LinkedIn:
“Kicking off 2026 with reflections on a standout event from late 2025: ESMO Asia Congress in Singapore—a pivotal gathering for advancing precision oncology across our region.
Delighted to have co-organized the symposium ‘AI-Powered Liquid Biopsy and Multi-Omics in Action’ with our team and esteemed faculty, chaired by Prof. Herbert Loong (The Chinese University of Hong Kong) and Prof. Nick Pavlakis (The University of Sydney). The session featured compelling insights from leading faculty including Asst. Prof. Aaron Tan Chia-Ken (National Cancer Centre Singapore), Dr. Le Son Tran (Medical Genetics Institute, Vietnam), Dr. Dang L. Nguyen (Medical Genetics Institute, Vietnam), and Prof. Aya El Helali (HKUMed – The University of Hong Kong)
The symposium sparked valuable dialogue with oncologists across Asia on translating regionally validated tools into earlier detection and more personalized patient care.
Discussions highlighted real-world evidence on:
- SPOT-MAS achieving 78.2% sensitivity, 99.8% specificity, 67% PPV, 99.9% NPV, and 80.3% tumor-of-origin accuracy in multi-cancer early detection across large Asian cohorts
- K-TRACK enabling ctDNA-MRD detection of relapse up to 14 months ahead of imaging, with validation across colorectal, breast, lung, HCC, and gastric cancers
- K-4CARE delivering integrated DNA (504 genes) and transcriptomic (19,435 genes) profiling with longitudinal monitoring—supporting complex decisions, including 87.7% tissue-of-origin accuracy in CUP and 20% improved fusion detection.
Separately, proud to share that Gene Solutions presented seven abstracts, with two earning Best Poster awards.
Grateful for the enriching discussions with Herbert Loong, Nick Pavlakis, Aaron Tan Chia-Ken, Aya El Helali, Rebecca Dent, Yew Oo Tan, Chern Siang Lee, Wendy Chan Wing Lok, Janice Tsang, Wen Son Hsieh, Cyril Titeux, Dianne Baunbaek, Huren Sivaraj, Kim Pong Kenny Ng and many others (a few moments captured here).
As we carry forward the momentum from 2025—including landmark publications in BMC Medicine and JCO Oncology Advances—excited to build on these insights and continue advancing accessible precision medicine in the year ahead across the globe.
For full details on our participation and key data presented, see the official press release.”    
More posts about ESMO Asia 2025.
